Bilateral germ cell testicular tumors in New Zealand: experience in Auckland and Christchurch 1978-1994.

Colls, B M; Harvey, VJ; Skelton, L.; Thompson, Paul; Frampton, Chris

doi:10.1200/jco.1996.14.7.2061

Cited by 64 publications

(52 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our data as well as previous studies [2,8,10,38] demonstrate that chemotherapy for a first TGCT does not prevent development of a second germ cell tumor. Fourteen of 33 patients in this series had received chemotherapy for their first TGCT.…”

Section: Discussionsupporting

confidence: 75%

See 1 more Smart Citation

Management and outcome of bilateral testicular germ cell tumors: Twenty-five year experience in Munich

Hentrich

Weber²,

Bergsdorf

et al. 2005

Acta Oncologica

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 75%

“…Because migration of patients between different institutions is usually not regarded a selection bias might have occurred. One study from New Zealand calculated the cumulative risk of developing a second TGCT to be 5.2% [8].…”

Section: Discussionmentioning

confidence: 99%

Management and outcome of bilateral testicular germ cell tumors: Twenty-five year experience in Munich

Hentrich

Weber²,

Bergsdorf

et al. 2005

Acta Oncologica

View full text Add to dashboard Cite

“…[6][7][8][9]12,13 Recent years' publications have addressed whether modern cisplatin-based chemotherapy might influence the effect of risk factors, but these results have also been inconclusive. 8,10,12,[14][15][16] Our hypothesis is that cisplatin-based chemotherapy, available since 1980 for patients with TGCT in Norway, reduces the risk of a metachronous contralateral TGCT. And any risk-reducing impact would be more evident for patients presenting with metastatic versus localized disease, as nearly all of the former ones have received such treatment, compared to only 20-25% in the latter group.…”

Section: Introductionmentioning

confidence: 99%

“…4,5 Patients with unilateral testicular germ cell tumor (TGCT) are at increased risk of developing a metachronous contralateral TGCT, with a cumulative incidence of 1-5%, [6][7][8] and a relative risk ranging from 12 to 36 compared to TGCT development in the general population. [7][8][9][10][11][12] Age below 30 years has been shown to be an important risk factor, whereas results regarding histology of the first primary (seminoma vs. nonseminoma) as risk factor for a second TGCT have been inconsistent. [6][7][8][9]12,13 Recent years' publications have addressed whether modern cisplatin-based chemotherapy might influence the effect of risk factors, but these results have also been inconclusive.…”

Section: Introductionmentioning

confidence: 99%

Risk of metachronous contralateral testicular germ cell tumors: A population‐based study of 7,102 Norwegian patients (1953–2007)

Andreassen

Grotmol

Cvancarova

et al. 2011

Intl Journal of Cancer

View full text Add to dashboard Cite

The purpose of the study was to identify overall incidence and risk of developing a metachronous contralateral testicular germ cell tumor (TGCT) and compare the risk for patients treated before and after 1980 (cisplatin became available for patients with metastatic TGCT). Our hypothesis was that the risk of metachronous TCGT would be reduced for patients with metastatic disease diagnosed after 1980. We included 7,102 men with unilateral TGCT, recorded in the Cancer Registry of Norway. Allowing for competing risk, cumulative incidence and adjusted hazard ratio (HR) were estimated for different subgroups, and the diagnostic periods 1953 -1979 (I) and 1980. Relative risks were assessed by standardized incidence ratio (SIR). In Period I and Period II, 38 and 137 males, respectively, were diagnosed with metachronous contralateral TGCT. Corresponding 20-year cumulative incidences were 1.9% and 3.9%. In Period II, risk of a second TGCT was halved [HR 5 0.5, 95% confidence interval (95% CI) 5 0.33-0.77] for patients with metastatic compared to localized disease. For patients presenting with localized and metastatic disease, the SIRs for Period I were 14.6 (95% CI 5 9.6-21.2) and 25.3 (95% CI 5 12.1-46.5), respectively. In Period II, the corresponding numbers were 19.0 (95% CI 5 15.6-22.9) and 9.8 (95% CI 5 6.4-14.5). In conclusion, the risk of metachronous contralateral TGCT was halved for patients with metastatic compared to localized disease in Period II, whereas this protective effect of extent of disease lacked significance for Period I. These findings support our hypothesis that cisplatin-based chemotherapy reduced the risk of a second TGCT for patients with metastatic TGCT diagnosed after 1980.

show abstract

“…In the absence of potent environmental risk factors for testicular cancer, this indicates the involvement of genetic factors in the aetiology of the disease (Khoury et al, 1988). The prevalence of bilateral testicular cancer in patients with unilateral testicular tumours varies between 1.0% and 5.8% (Osterlind et al, 1991;Colls et al, 1996;Sonneveld et al, 1998). Patients with bilateral involvement of paired organs, including the testes, are generally considered to be at high risk of having a genetic predisposition to the disease.…”

Section: Discussionmentioning

confidence: 99%

Geographic clustering of testicular cancer incidence in the northern part of The Netherlands

et al. 1999

View full text Add to dashboard Cite

Geographic variations in testicular cancer incidence may be caused by differences in environmental factors, genetic factors, or both. In the present study, geographic patterns of age-adjusted testicular cancer incidence rates (IRs) in 12 provinces in The Netherlands in the period 1989–1995 were analysed. In addition, the age-adjusted IR of testicular cancer by degree of urbanization was evaluated. Cancer incidence data were obtained from the Netherlands Cancer Registry. The overall annual age-adjusted IR of testicular cancer in The Netherlands in the period 1989–1995 was 4.4 per 100 000 men. The province Groningen in the north of the country showed the highest annual IR with 5.8 per 100 000 men, which was higher ( P < 0.05) than the overall IR in The Netherlands (incidence rate ratio (IRR) 1.3, 95% confidence interval (CI) 1.1–1.6). The highest IR in Groningen was seen for both seminomas and non-seminomas. In addition, Groningen showed the highest age-specific IRs in all relevant younger age groups (15–29, 30–44 and 45–59 years), illustrating the consistency of data. The province Friesland, also situated in the northern part of the country, showed the second highest IR of testicular cancer with 5.3 cases per 100 000 men per year (IRR 1.2, 95% Cl 1.0–1.5, not significant). This mainly resulted from the high IR of seminoma in Friesland. Analysis of age-adjusted IRs of testicular cancer by degree of urbanization in The Netherlands showed no urban–rural differences at analysis of all histological types combined, or at separate analyses of seminomas and non-seminomas. Geographic clustering of testicular cancer seems to be present in the rural north of The Netherlands with some stable founder populations, which are likely to share a relatively high frequency of genes from common ancestors including genes possibly related to testicular cancer. Although this finding does not exclude the involvement of shared environmental factors in the aetiology of testicular cancer, it may also lend support to a genetic susceptibility to testicular cancer development. Testicular cancer cases in stable founder populations seem particularly suitable for searching for testicular cancer susceptibility genes because such genes are likely to be more frequent among affected men in such populations. © 1999 Cancer Research Campaign

show abstract

Bilateral germ cell testicular tumors in New Zealand: experience in Auckland and Christchurch 1978-1994.

Abstract: Men who are cured of a germ cell testicular cancer have a greatly increased risk of developing a second testicular cancer. Such patients should be informed of this risk and ideally kept under long-term surveillance.

Cited by 64 publications

References 0 publications

Management and outcome of bilateral testicular germ cell tumors: Twenty-five year experience in Munich

Management and outcome of bilateral testicular germ cell tumors: Twenty-five year experience in Munich

Risk of metachronous contralateral testicular germ cell tumors: A population‐based study of 7,102 Norwegian patients (1953–2007)

Geographic clustering of testicular cancer incidence in the northern part of The Netherlands

Contact Info

Product

Resources

About